---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Contraindications/Warnings/Precautions/Adverse effects"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Contraindications/Warnings/Precautions/Adverse effects. Covers Warnings and precautions. 17 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/contraindications-warnings-precautions-adverse-effects"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Contraindications/Warnings/Precautions/Adverse effects

<a id="heading-2.1.2.7"></a>

## 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

#### Boxed warning: hearing impairment including permanent hearing loss

> “Treatment with LEMBAZ has resulted in permanent hearing impairment.”
> “Prior to LEMBAZ use, perform a comprehensive audiology evaluation (e.g., pure tone audiometry, speech recognition, tympanometry) to establish baseline hearing levels”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss.”
> “A comprehensive hearing evaluation should be performed on patients before starting Lembaz and regularly throughout treatment, and dose adjustments may be needed based on the results of these evaluations.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.1.2.7.1-2"></a>

#### Contraindications

> “CONTRAINDICATIONS None.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-3"></a>

#### Hearing impairment: warning and precaution

> “LEMBAZ can cause hearing impairment.”
> “LEMBAZ-treated patients experienced permanent hearing impairment that ranged from mild to profound hearing loss, including in some patients with normal hearing at baseline.”
> “Observed hearing impairment predominantly impacted higher frequencies (at least 2,000 to 8,000 Hz) but hearing impairment at mid and lower frequencies (500 to 2,000 Hz) was also observed”
> “Do not increase the dosage if hearing impairment is observed as defined in subsection 2.3”
> “In patients with LEMBAZ-associated hearing impairment, there are insufficient data to determine if continuing treatment at the current dosage increases the risk of further hearing impairment or if lowering the LEMBAZ dosage reduces the risk of additional hearing impairment.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-4"></a>

#### Hearing impairment with audiometry-guided titration in Trial 3 and the expanded access program

> “Hearing Impairment: In single-arm studies (Trial 3 and an expanded access program) [see Clinical Studies (14)], the safety of LEMBAZ was assessed in 59 patients who received a starting LEMBAZ dosage of 200 mg every 2 weeks given intrathecally (less than 4 years of age), or 400 mg every 2 weeks (4 years of age or older) given intrathecally.”
> “The dosage was increased to a maximum of up to 600 mg (for patients who weighed 7 to 12 kg) or up to 900 mg (for patients who weighed more than 12 kg) given intrathecally every 2 weeks.”
> “In Trial 3 and an expanded access program which used upward titration guided by audiometry, 37% (22/59) of patients treated with LEMBAZ experienced hearing impairment”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-5"></a>

#### Ataxia: warning and precaution

> “LEMBAZ can cause ataxia, including fall, abnormal gait and/or coordination, dizziness, and hypotonia.”
> “The severity of ataxia may be associated with a higher LEMBAZ dosage.”
> “Monitor LEMBAZ-treated patients for ataxia severity.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “Severe ataxia requiring hospitalization has occurred.”

Source: [LEMBAZ dosing and administration guide (2026)](https://lembazrx.com/wp-content/uploads/dosing-administration-guide.pdf)

<a id="topic-2.1.2.7.1-6"></a>

#### Fatigue: warning and precaution

> “LEMBAZ can cause fatigue, including asthenia, fatigue, malaise, and somnolence.”
> “One patient treated with LEMBAZ 900 mg every 2 weeks required hospitalization for a severe fatigue event on the day of treatment.”
> “The severity of fatigue may be associated with a higher LEMBAZ dosage.”
> “Monitor LEMBAZ-treated patients for fatigue.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-7"></a>

#### Safety population and most common adverse reactions

> “The safety of LEMBAZ was evaluated in 141 patients with NPC (including 80 patients with NPC with neurological symptom manifestation onset at less than 6 years of age) who received at least one LEMBAZ dose given by intrathecal administration”
> “The most common adverse reactions (≥25% of patients treated with LEMBAZ and greater in LEMBAZ-treated patients than those in the sham control group) were hearing impairment, ataxia, fatigue, vomiting, back pain, headache, pyrexia, diarrhea, nausea, and cough.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

> “The most common side effects of Lembaz include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.1.2.7.1-8"></a>

#### Common adverse reactions through Week 52 in Trial 1 Parts A and B

> “Common adverse reactions were those reported in ≥10% of LEMBAZ-treated patients, and greater in LEMBAZ-treated patients than those in the sham control group.”
> “Subgroup of treatment arm that received LEMBAZ ≤900 mg.”
> “Hearing impairment includes other similar terms and hypoacusis, tinnitus, deafness, and abnormal tympanometry.”
> “Ataxia includes gait disturbance, fall, dizziness, dyskinesia, balance disorder, bradykinesia, abnormal coordination, dysstasia, vertigo.”
> “Fatigue includes asthenia, malaise, somnolence.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

| Preferred term | Adrabetadex up to 900 mg (N=32), n (%) | Sham (N=18), n (%) |
| --- | --- | --- |
| Hearing impairment | “23 (71.9)” | “8 (44.4)” |
| Ataxia | “22 (68.8)” | “5 (27.8)” |
| Fatigue | “18 (56.3)” | “5 (27.8)” |
| Vomiting | “17 (53.1)” | “3 (16.7)” |
| Back pain | “16 (50.0)” | “3 (16.7)” |
| Headache | “14 (43.8)” | “3 (16.7)” |
| Pyrexia | “13 (40.6)” | “3 (16.7)” |
| Diarrhea | “10 (31.3)” | “1 (5.6)” |
| Nausea | “8 (25.0)” | “1 (5.6)” |
| Cough | “8 (25.0)” | “4 (22.2)” |
| Contusion | “6 (18.8)” | “2 (11.1)” |
| Pain in extremity | “6 (18.8)” | “1 (5.6)” |
| Epistaxis | “5 (15.6)” | “1 (5.6)” |
| Urinary incontinence | “5 (15.6)” | “1 (5.6)” |
| Muscular weakness | “5 (15.6)” | “0 (0)” |
| Dysarthria | “4 (12.5)” | “1 (5.6)” |
| Skin abrasion | “4 (12.5)” | “1 (5.6)” |
| Nasopharyngitis | “4 (12.5)” | “2 (11.1)” |

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-9"></a>

#### Adverse reactions in participants less than 4 years of age

> “In Trial 3 and an expanded access program, 23 patients less than 4 years of age received a starting LEMBAZ dosage of 200 mg every 2 weeks given intrathecally, and the dosage was increased up to a maximum of 600 mg (for patients who weighed 7 to 12 kg) or 900 mg (for patients who weighed more than 12 kg) every 2 weeks given intrathecally.”
> “Adverse reactions were similar when compared to patients 4 years of age or older who received LEMBAZ at a dosage up to 900 mg in Trial 1.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-10"></a>

#### Onset and duration of ataxia and fatigue events

> “Ataxia: Of the ataxia adverse reactions that occurred in LEMBAZ-treated patients, the ataxia started within 3 days of LEMBAZ administration in 61% (107/174) of events.”
> “Ataxia adverse reactions resulted in dosage interruptions in 6% (2/32) of LEMBAZ-treated patients”
> “Fatigue: Of the fatigue adverse reactions that occurred in LEMBAZ-treated patients, the fatigue started within 3 days of LEMBAZ administration in 91% (87/96) of events.”
> “The duration of fatigue ranged from 1 to 76 days, with a median duration of 2 days”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-11"></a>

#### Aspiration pneumonia, including one fatal event after administration with sedation

> “Aspiration Pneumonia: In Trial 1 Parts A and B, 9% (3/32) of LEMBAZ-treated patients experienced aspiration pneumonia compared to 6% (1/18) of sham-treated patients.”
> “In Trial 1 Part C, a single patient experienced an aspiration event resulting in fatal aspiration pneumonia after they received LEMBAZ with sedation.”
> “It is unclear whether the aspiration pneumonia was due to LEMBAZ, sedation, and/or underlying NPC disease.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-12"></a>

#### Overdosage at 1,200 mg and 1,800 mg

> “In Trial 1 Part A [see Clinical Studies (14)], 3 patients received 1,200 mg of LEMBAZ (1.3 times maximum recommended dosage) and 3 patients received 1,800 mg of LEMBAZ (2 times the maximum recommended dosage).”
> “There was a higher rate of ataxia and fatigue, and greater severity of hearing impairment, ataxia, and fatigue in patients who received these dosages, compared to those who received the maximum recommended dose of 900 mg.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-13"></a>

#### Nonclinical carcinogenicity and mutagenicity

> “There was no evidence of a primary carcinogenic effect in mice given daily oral doses of up to 5,000 mg/kg for approximately 2 years.”
> “In rats, administration of adrabetadex at 5,000 mg/kg/day (11 times greater than the MRHD based on body surface area) for approximately 2 years increased the incidence of soft tissue combined malignant sarcoma and fibrosarcoma in males and exocrine pancreatic tumors (benign adenoma and combined benign adenoma/malignant adenocarcinoma) in females.”
> “Adrabetadex was not mutagenic or clastogenic in a battery of in vitro and in vivo assays including bacterial reverse mutation (Ames), unscheduled DNA synthesis in primary rat hepatocytes, mouse lymphoma forward mutation, chromosomal aberration in human lymphocytes, and mouse micronucleus assays.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-14"></a>

#### Patient counseling on hearing impairment, ataxia, and fatigue

> “Advise patients and/or their caregivers about the risks of permanent hearing impairment with LEMBAZ treatment, and that comprehensive audiology evaluations should be performed before and during treatment”
> “Advise patients and/or their caregivers that ataxia may occur after LEMBAZ administration”
> “Advise patients and/or their caregivers that fatigue may occur after LEMBAZ administration”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.7.1-15"></a>

#### Ototoxicity of 2-hydroxypropyl-beta-cyclodextrin across species: review

> “Despite the potential health benefits, use of HPβCD has been linked to significant hearing loss in several species, including humans.”
> “Ototoxicity can occur following central or peripheral drug delivery, with either route resulting in the preferential loss of cochlear outer hair cells (OHCs) within hours of dosing.”
> “The long-term impact of HPβCD use as a maintenance drug, and the mechanism(s) of ototoxicity, are unknown.”
> “Yet, Kleptose HPB (aka VTS-270) is ototoxic in mice and humans (Davidson et al., 2016; Ory et al., 2017).”
> “Thus, seemingly innocuous doses can become devastating to the ear if administered by different routes close in time.”
> “The risk for functionally significant hearing loss before development of speech and language should be weighed carefully with potential benefits of early-life treatment of the disease.”

Source: [Crumling et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5676048/)

<a id="topic-2.1.2.7.1-16"></a>

#### Hearing threshold elevation with intracisternal administration in cats

> “An increase in hearing threshold was identified as a potential adverse effect.”
> “Our studies in the cat indicate that chronic HPβCD at therapeutic doses is always accompanied by severe hearing loss.”
> “These findings have important implications for clinical use in human patients where deafness may be an expected outcome of therapy.”

Source: [Vite et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4415615/)

<a id="topic-2.1.2.7.1-17"></a>

#### Adverse events after repeated lumbar puncture for intrathecal delivery at Rush University Medical Center

> “Of the 59 patients treated 33 (55.9%) had no adverse events ever after an LP and 26 (44.1%) had adverse effects at some time.”
> “Of the 2935 LPs, adverse events occurred after 3.3% of LPs.”
> “Adverse events most observed were headache (1.2% of LPs), nausea (0.3%), vomiting (1.0%), and back pain (1.3%).”
> “This study shows that frequent repeated LPs are possible for delivery of intrathecal therapy and can be accomplished with a very low rate of post-LP adverse events.”

Source: [Albert et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37201244/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
